Proven and unproven therapy for benign prostatic hyperplasia

New England Journal of Medicine

Volumn 354, Issue 6, 2006, Pages 632-634

  DiPaola, Robert S ^a   Morton, Ronald A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; HERBACEOUS AGENT; PLACEBO; PLANT EXTRACT; SAW PALMETTO EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; CARDIOTOXICITY; CLINICAL TRIAL; COURSE EVALUATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; ESTROGEN ACTIVITY; FOOD AND DRUG ADMINISTRATION; GANODERMA LUCIDUM; GINSENG; HUMAN; PATIENT ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RABDOSIA; SABAL; SAMPLE SIZE; SCORING SYSTEM; SCUTELLARIA; SELF MEDICATION; URINE FLOW RATE;

ANDROGEN ANTAGONISTS; DRUG APPROVAL; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; TREATMENT FAILURE;

EID: 32144456375     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe058301     Document Type: Editorial

References (15)

1. Osler W. Aequanimitas. 2nd ed. Philadelphia: P. Blakiston's Son & Co., 1928.
2. Angell M, Kassirer JP. Alternative medicine - the risks of untested and unregulated remedies. N Engl J Med 1998;339:839-41.
3. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557-66.
4. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280:1604-9.
5. [Erratum, JAMA 1999;281:515.]
6. Wilt T, Ishani A, Stark G, MacDonald R, Mulrow C, Lau J. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000;2:CD001423.
7. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-9.
8. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
9. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231-40.
10. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002;41:497-507.
11. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339:785-91.
12. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004;22:3705-12.
13. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58:Suppl 1:108-13.
14. Buck AC. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 2004;172:1792-9.
15. Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001;57:999-1005.